Ovagen 20 mg

Ovagen 20 mg contains the EDL tripeptide, a synthetic peptide bioregulator studied for its proposed interaction with renal and hepatic cell DNA. No human clinical trials have evaluated Ovagen for any indication, and all use outside research applications falls outside approved indications. Community observational reports indicate users have selected libido and recovery as reported benefits, though overall experience ratings are mixed.

Community observational data indicates a median dose bucket of 2+ mg per injection, with administration frequency varying by protocol. These figures are anecdotal and not medically established, as no human trial has established a safe or effective dose.

No. Ovagen acts on cellular gene expression and chromatin remodeling rather than the hypothalamic-pituitary-gonadal axis. It does not suppress endogenous testosterone production, so post-cycle therapy in the context of testosterone recovery is not applicable.

Ovagen is proposed to regulate renal cell function and provide hepatoprotection through direct DNA binding and modulation of gene expression. The proposed mechanism involves interaction with AT-rich regions in gene promoter areas, leading to chromatin decondensation and increased transcription of genes involved in tissue function. The specific molecular targets and mechanisms have not been independently validated.

The time course for Ovagen is not established in humans. As a tripeptide, Ovagen is expected to be rapidly degraded by peptidases in plasma and tissues, limiting systemic exposure duration. Any cumulative effects on gene expression would develop over the course of administration, though no human data exist to characterize onset of action.

There is no evidence-based “best” tissue-support peptide. Ovagen is proposed to act through renal and hepatic gene regulation, while BPC 157 is studied for angiogenesis and tissue repair through a different mechanism. The appropriate approach depends on individual goals and circumstances, and all non-medical use falls outside approved indications.

Both are synthetic tripeptide bioregulators developed by Vladimir Khavinson, but they target different tissues. Ovagen (Glu-Asp-Leu) is studied for renal cell function and hepatoprotection, while Livagen is investigated for liver tissue and chromatin remodeling. The two peptides have distinct amino acid sequences and proposed tissue targets.

Ovagen (Glu-Asp-Leu) is studied for renal and hepatic tissue effects, while Epitalon (Ala-Glu-Asp-Gly) is investigated for pineal gland effects and telomerase activation. Both are Khavinson bioregulator peptides with tissue-specific effects, but they have different amino acid sequences and research applications.

The 20 mg vial strength provides flexibility for reconstitution and dosing. Community observational data indicates a median dose bucket of 2+ mg per injection, so a single 20 mg vial would provide multiple doses depending on the protocol. Because dosing is not clinically established, the appropriate amount should be based on research context rather than a fixed protocol.

Ovagen 20 mg is labeled at 20 mg of Ovagen (EDL tripeptide) per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

No published laboratory report is currently available for this specific product. Product potency and purity verification would apply to tested samples only and should not be interpreted as a measurement of every vial or production batch.

Lyophilized Ovagen is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.